论文部分内容阅读
肌萎缩侧索硬化(ALS)是一种进行性神经系统变性疾病,病因及发病机制尚未明确,目前也缺乏适当的治疗,本文旨在探讨谷氨酸拮抗剂Riluzole对ALS病人的疗效及其安全性。 本研究系一前瞻性、随机双盲、安慰剂对照试验。自1990年6月～1990年11月选择155例门诊病人,年龄20～75岁,确诊或高度拟似ALS。根据起病部位分为延髓起病型32例,肢体起病型123例。77例随机分入Riluzole治疗组,包括62例肢体起病型,15例延髓起病型;78例分入安慰剂对照组,其中肢体起病型61例,延髓起病型17例。治疗组给予
Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disease of the nervous system. The etiology and pathogenesis of ALS are not yet clear. At present, there is a lack of proper treatment. This article aims to investigate the efficacy and safety of glutamate antagonist Riluzole in patients with ALS Sex. This study was a prospective, randomized, double-blind, placebo-controlled trial. From June 1990 to November 1990, 155 outpatients were selected, aged from 20 to 75 years, with confirmed or highly probable ALS. According to the diseased part is divided into bulbar onset type 32 cases, 123 cases of limb onset type. Totally 77 patients were randomly divided into Riluzole treatment group, including 62 cases of limb onset and 15 cases of bulbar onset; 78 cases were divided into placebo control group, of which 61 cases of limb onset and 17 cases of bulging onset. Treatment group given